LONN Stock Overview
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally.
No risks detected for LONN from our risk checks.
Lonza Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF555.00|
|52 Week High||CHF785.40|
|52 Week Low||CHF510.60|
|1 Month Change||-10.46%|
|3 Month Change||-8.63%|
|1 Year Change||-3.48%|
|3 Year Change||75.97%|
|5 Year Change||173.00%|
|Change since IPO||504.58%|
Recent News & Updates
|LONN||CH Life Sciences||CH Market|
Return vs Industry: LONN exceeded the Swiss Life Sciences industry which returned -9.3% over the past year.
Return vs Market: LONN underperformed the Swiss Market which returned -1.9% over the past year.
|LONN Average Weekly Movement||4.5%|
|Life Sciences Industry Average Movement||7.1%|
|Market Average Movement||4.9%|
|10% most volatile stocks in CH Market||8.5%|
|10% least volatile stocks in CH Market||2.5%|
Stable Share Price: LONN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: LONN's weekly volatility (5%) has been stable over the past year.
About the Company
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals.
Lonza Group Fundamentals Summary
|LONN fundamental statistics|
Is LONN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LONN income statement (TTM)|
|Cost of Revenue||CHF3.30b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Jul 22, 2022
|Earnings per share (EPS)||9.08|
|Net Profit Margin||12.46%|
How did LONN perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is Lonza Group undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LONN (CHF555) is trading below our estimate of fair value (CHF1300.49)
Significantly Below Fair Value: LONN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LONN is poor value based on its Price-To-Earnings Ratio (61.1x) compared to the Swiss Life Sciences industry average (45.7x).
PE vs Market: LONN is poor value based on its Price-To-Earnings Ratio (61.1x) compared to the Swiss market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: LONN is poor value based on its PEG Ratio (3.3x)
Price to Book Ratio
PB vs Industry: LONN's Price-To-Book Ratio (4.2x) is in line with the CH Life Sciences industry average.
How is Lonza Group forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LONN's forecast earnings growth (18.6% per year) is above the savings rate (-0.3%).
Earnings vs Market: LONN's earnings (18.6% per year) are forecast to grow faster than the Swiss market (5.9% per year).
High Growth Earnings: LONN's earnings are forecast to grow, but not significantly.
Revenue vs Market: LONN's revenue (11.2% per year) is forecast to grow faster than the Swiss market (4.3% per year).
High Growth Revenue: LONN's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LONN's Return on Equity is forecast to be low in 3 years time (12.2%).
How has Lonza Group performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LONN has high quality earnings.
Growing Profit Margin: LONN's current net profit margins (12.5%) are lower than last year (16.2%).
Past Earnings Growth Analysis
Earnings Trend: LONN's earnings have grown by 7.3% per year over the past 5 years.
Accelerating Growth: LONN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LONN had negative earnings growth (-7.7%) over the past year, making it difficult to compare to the Life Sciences industry average (50.8%).
Return on Equity
High ROE: LONN's Return on Equity (6.9%) is considered low.
How is Lonza Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: LONN's short term assets (CHF6.0B) exceed its short term liabilities (CHF2.4B).
Long Term Liabilities: LONN's short term assets (CHF6.0B) exceed its long term liabilities (CHF4.3B).
Debt to Equity History and Analysis
Debt Level: LONN has more cash than its total debt.
Reducing Debt: LONN's debt to equity ratio has reduced from 79.9% to 24.6% over the past 5 years.
Debt Coverage: LONN's debt is well covered by operating cash flow (50.4%).
Interest Coverage: LONN's interest payments on its debt are well covered by EBIT (10.8x coverage).
What is Lonza Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: LONN's dividend (0.54%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.91%).
High Dividend: LONN's dividend (0.54%) is low compared to the top 25% of dividend payers in the Swiss market (3.88%).
Stability and Growth of Payments
Stable Dividend: LONN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: LONN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: LONN is not paying a notable dividend for the Swiss market.
Cash Payout to Shareholders
Cash Flow Coverage: LONN is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pierre-Alain Ruffieux (52 yo)
Dr. Pierre-Alain Ruffieux, PhD has been the Chief Executive Officer at Lonza Group Ltd since November 1, 2020. Dr. Ruffieux served as Head of Global Pharma Technical Operations at Roche where he and his te...
CEO Compensation Analysis
Compensation vs Market: Pierre-Alain's total compensation ($USD4.16M) is about average for companies of similar size in the Swiss market ($USD4.89M).
Compensation vs Earnings: Pierre-Alain's compensation has been consistent with company performance over the past year.
Experienced Management: LONN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: LONN's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lonza Group AG's employee growth, exchange listings and data sources
- Name: Lonza Group AG
- Ticker: LONN
- Exchange: SWX
- Founded: 1897
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF41.175b
- Shares outstanding: 74.19m
- Website: https://www.lonza.com
Number of Employees
- Lonza Group AG
- Muenchensteinerstrasse 38
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.